Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib

Arthritis Care and Research

Volumn 59, Issue 8, 2008, Pages 1105-1111

  Setakis, E ^a   Leufkens, H G M ^b   Van Staa, T P ^a,b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; EVALUATION; FEMALE; FRAMINGHAM RISK SCORE; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT DURATION; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; FEMALE; GASTROINTESTINAL DISEASES; GREAT BRITAIN; HUMANS; INCIDENCE; LACTONES; LOGISTIC MODELS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; RHEUMATIC DISEASES; RISK FACTORS; SULFONES;

EID: 49549086408     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23925     Document Type: Article

References (14)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, and the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
3. European Medicines Agency. URL: http://www.emea.europa.eu/htms/human/ press/cox2QA.htm.
4. Mosis G, Stijnen T, Castellsague J, Dieleman JP, van der Lei J, Stricker BH, et al. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs. Arthritis Rheum 2006;55:537-42.
5. Dai C, Stafford RS, Alexander C. National trends in cyclooxygenase-2 inhibitor use since market release. Arch Intern Med 2005;165:171-7.
6. Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 2007;16:891-900.
7. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9.
8. Van Staa TP, Abenhaim L. The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 1994;3:15-21.
9. Jick H, Derby LE, Gurewich V, Vasilakis C. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996;16:321-6.
10. Anderson KM, Odell PM, Wilson WF, Kannel WB. Cardiovascular disease risk profiles. Am Heart Journal 1990;121:293-8.
11. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal hemorrhage in users of meloxicam, coxibs, and older, nonspecific nonsteroidal antiinflammatory drugs. Gut 2003;52:1265-70.
12. Van Staa TP, Smeeth L, Persson I, Parkinson J, Leufkens HG. What is the harm-benefit ratio of COX-2 inhibitors? Int J Epidemiol 2008;37:405-13.
13. Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription nonsteroidal antiinflammatory drugs (NSAIDS) in UK and USA populations: implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006;15:861-72.
14. Van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005;98:191-8.